

Mahasti Saghatchian

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9397333/publications.pdf>

Version: 2024-02-01

9
papers

104
citations

1937457

4
h-index

1719901

7
g-index

10
all docs

10
docs citations

10
times ranked

132
citing authors

#	ARTICLE	IF	CITATIONS
1	Feasibility of personalized screening and prevention recommendations in the general population through breast cancer risk assessment: results from a dedicated risk clinic. <i>Breast Cancer Research and Treatment</i> , 2022, 192, 375-383.	1.1	5
2	Abstract P1-18-09: Impact of prior adjuvant trastuzumab (aT) on clinical characteristics, patterns of recurrence and outcomes in 4145 patients with Her2 positive (HER2+) metastatic breast cancer (MBC)- Results from the French ESME UNICANCER program. <i>Cancer Research</i> , 2022, 82, P1-18-09-P1-18-09.	0.4	0
3	BEAUTY and the breast: is adjuvant chemotherapy the right time for a beauty boost? Lessons learned from a large randomized controlled trial. <i>Quality of Life Research</i> , 2021, , 1.	1.5	2
4	Multicenter evaluation of breast cancer patients'™ satisfaction and experience with oncology telemedicine visits during the COVID-19 pandemic. <i>British Journal of Cancer</i> , 2021, 125, 1486-1493.	2.9	37
5	PARP Inhibitors in Breast Cancer: <i>Why, How, and When?</i> . <i>Breast Care</i> , 2018, 13, 216-219.	0.8	4
6	Long-term outcome of the REMAGUS 02 trial, a multicenter randomised phase II trial in locally advanced breast cancer^patients treated with neoadjuvant chemotherapy with or without celecoxib or trastuzumab according to HER2 status. <i>European Journal of Cancer</i> , 2017, 75, 323-332.	1.3	22
7	The challenge of rapid diagnosis in oncology: Diagnostic accuracy and cost analysis of a large-scale one-stop breast clinic. <i>European Journal of Cancer</i> , 2016, 66, 131-137.	1.3	33
8	Uncovering Professional Attitudes Toward Treatment of Rare Carcinomas of the Breast: An International Practice e-Survey Involving 32 Countries. <i>Breast Journal</i> , 2016, 22, 96-100.	0.4	0
9	Nonmetastatic inflammatory breast cancer: Evolution of invasive disease-free (IDFS) and overall survival (OS) over a 21-year period.. <i>Journal of Clinical Oncology</i> , 2014, 32, 1082-1082.	0.8	0